Emerging studies suggest Retatrutide , a dual stimulator targeting both GLP-1 and GIP , could represent a significant advancement for body loss . Early clinical tests have demonstrated considerable losses in visceral tissue, possibly exceeding existing body composition medications . However , additional study is needed to completely assess its long